Amicus Therapeutics

company

About

Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.

  • 501 - 1000

Details

Last Funding Type
Series C
Last Funding Money Raised
$55M
Industries
Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2002
Number Of Employee
501 - 1000
Operating Status
Active

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$55M
Amicus Therapeutics has raised a total of $55M in funding over 2 rounds. Their latest funding was raised on Sep 8, 2005 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 8, 2005 Series C $55M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Amicus Therapeutics is funded by 1 investors. Garden State Life Sciences Venture are the most recent investors.
Investor Name Lead Investor Funding Round
Garden State Life Sciences Venture Series C